Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
19 September 2022 | Story André Damons | Photo André Damons
Sithembiso Ndlovu
Sithembiso Ndlovu is a lecturer in the Dean’s Office, Faculty of Health Sciences who recently completed his research into the impact the COVID-19 pandemic had on gender-based violence (GBV) among women.

A lecturer at the University of the Free State (UFS) Faculty of Health Sciences hopes his research into the impact the COVID-19 pandemic had on gender-based violence (GBV) among women, could assist the victims and especially government and organisations to address this evil post-COVID-19. 

Sithembiso Ndlovu, a Public Health Lecturer in the Division of Public Health, Office of the Dean of Health Sciences, says this research was a narrative review paper which aimed to explore the impact of the COVID-19 pandemic on GBV among women since there is inadequate established literature on this topic, particularly in South Africa. The focus was on intimate partner violence.

He started working on the review in February 2021 and finished in August the same year where after the paper was published by the African Journal of Reproductive Health (AJRH) in July 2022. He says he believes his research aligns with the UFS narrative of creating opportunities and growth through leading, learning and teaching, focused research, and impactful engagement with society given the quality of the research that his review upholds. 

Looking at the state and impact of GBV

Says Ndlovu: “I believe my research will be impactful in academia and in the lives of women who experienced GBV during lockdown. The study will also be impactful to women who will experience GBV in the future through recommended interventions, which I believe government departments and various GBV-oriented organisations can adopt to curb the increase in GBV cases in the country post-COVID-19 pandemic. 

”All in all, the research expresses the notion of care for the well-being of South African women who are voiceless or powerless and thus creates an opportunity for them to be able to seek help.”

The researcher says he wanted to look at the state and impact of GBV among women during the pandemic in the South African context and lay a foundation for prospective interventions to mitigate the increase of GBV cases during the lockdown. He envisages government departments and local organisations that deal with issues relating to GBV to consider the proposed interventions. 

“Also, it remains vital to engage men on the importance of GBV and the role they can play in decreasing the prevalence of this second pandemic after the COVID-19 as President Cyril Ramaphosa noted,” says Ndlovu.

According to him, without proper and accessible support, there will always be an increased risk of victimisation, even in households where there was no violence before the lockdown. Multipronged and all-inclusive intervention strategies are needed to address the prevalence of GBV cases effectively and sufficiently in South Africa. 

What does the research show? 

Ndlovu says the research found that there are multiple factors that contributed to the surge in GBV cases in South Africa, including alcohol availability and consumption, job losses, financial dependence, psychological distress, and emotional imbalances during the lockdown. During the restrictive lockdown, women were more exposed to the aggressors at home, where varying hostile power dynamics prevail, leaving the victims with limited opportunity to find any potential help and support due to limited mobility.

“When I was drafting the paper, there was limited literature on GBV during COVID-19 and comparing and contrasting statistics between the two periods was challenging. At the start of lockdown in March 2020, 87 000 cases of GBV and interpersonal violence were reported, a significant increase compared to pre-COVID-19. 

“However, the reports did not specify the type of interpersonal violence, and GBV reported or the gender of the aggressor although it has been widely reported that male partners perpetrate most IPV.” 

Interventions

Ndlovu wrote in the research article that key intervention strategies in combating GBV and ensuring that victims are supported adequately include dialogues and interventions around high-level communication and behaviour change programmes, prioritisation of reported cases, and developing interventions tailored to respond to the economically vulnerable circumstances women encounter. 

“There should be an emergency strengthening of the support systems that could be utilised by women experiencing violence and who are planning to escape the violent environment during regulated lockdown curfew periods in South Africa.

“Interventions should also include denormalising violence against women by their male counterparts and men in general. This could be implemented through educational programmes in communities, including schools where violence is prevalent. In this regard, an evaluation study on a school violence programme in Tshwane found that the programme increased positive knowledge of violence and attitudes toward violence. The recommended services must also be offered in all South African official languages to ensure that information is received and understood extensively,” he wrote. 

GBV-related programmes need to be prioritised in every sector and government department. This would necessitate realistic measures and activities to ensure impact. Governments must collaborate with various organisations to derive interventions by eliminating factors contributing to a surge in GBV cases. 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept